Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS-Melanoma
NL-OMON55920Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, ipilimumab, tobemstomig, atezolizumab and tiragolumab in melanoma and cutaneous malignancy (5 cohorts), sponsored by Roche. Primary endpoint: Pathologic response rate. Started Mar 2022; status: completed.
02
Drugs
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON55920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55920.